GlassScriptPhysician profile
Spencer A Wilson
NPI 1679731046
$12,374.04
in general payments reported to CMS, 2019-2025
39 companies · $2,007 in 2025
The $2,007 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $820 · 2021: $2,047 · 2022: $2,295 · 2023: $1,991 · 2024: $1,881 · 2025: $2,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,774 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,773.62 |
| Education | $105.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,979.99 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,127.26 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,389.96 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $781.53 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $559.20 | 2021-2024 | Zeposia |
| Pfizer INC. | $464.51 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $296.28 | 2020-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $236.73 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $221.19 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $194.11 | 2019-2022 | |
| Ardelyx, INC. | $168.42 | 2023-2025 | Ibsrela |
| Allergan, INC. | $147.35 | 2019 | |
| Redhill Biopharma INC. | $141.45 | 2020-2022 | |
| Braintree Laboratories, INC. | $138.25 | 2019-2024 | Sutab, Suflave |
| Celltrion USA INC. | $138.05 | 2023-2025 | Zymfentra, Yuflyma, Vegzelma |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $132.18 | 2022-2025 | |
| Romark Laboratories, Lc | $120.45 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $119.08 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $114.26 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $106.16 | 2019-2023 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $103.77 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $90.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $87.72 | 2024 | |
| Ucb, INC. | $81.95 | 2019 | |
| Sandoz INC. | $67.99 | 2023-2024 | Hyrimoz |
| Lilly USA, LLC | $44.99 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $43.92 | 2019-2024 | |
| Boston Scientific Corporation | $34.66 | 2025 | Watchman Flx |
| Medtronic, INC. | $33.99 | 2021-2025 | Intellis Adaptivestim |
| Mauna Kea Technologies, INC. | $33.20 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $32.54 | 2022-2023 | |
| Concordia Pharmaceuticals INC. | $24.90 | 2019 | |
| Novo Nordisk INC | $23.80 | 2025 | Wegovy |
| Axonics, INC. | $19.21 | 2022 | |
| Vivus LLC | $16.75 | 2022 | |
| Amgen INC. | $16.43 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $16.31 | 2019 | |
| Organon LLC | $14.12 | 2023 | Renflexis |
| Alexion Pharmaceuticals, INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.